How to find a Swiss distribution partner

What are the four partner models?

There are four models: a Swiss subsidiary of your own holding its own authorisation, a service provider that holds the authorisation for you, a distribution partner that holds the authorisation itself, or a pure logistics mandate with a third party while you supply the marketing-authorisation holder.

Your own subsidiary gives full control and carries fixed costs from day one. The service provider, often called a service MAH, holds the authorisation in its name while brand, pricing strategy and customer relationship stay with you; you pay an annual retainer plus pass-through costs. A distribution partner that holds the authorisation itself costs you nothing upfront and usually buys at a transfer price, but afterwards it owns market access.

The fourth model separates regulation from physical flow: a logistics provider or 3PL with a wholesale Betriebsbewilligung stores, picks and delivers to wholesalers, hospitals and pharmacies, while your own Zulassungsinhaberin carries the regulatory responsibility. It is the most control-heavy model without a country organisation, but it demands regulatory and pharmacovigilance capacity of your own.

What do you check before signing?

Check the licences first, then the conflict of interest, then market coverage. A partner without a Betriebsbewilligung for the activities you need is not a partner, it is a project. Ask for copies of the licence and the latest inspection report, plus the name of the fachtechnisch verantwortliche Person.

The Betriebsbewilligung is activity-specific: import, wholesale and batch release for the market are listed separately. A wholesaler-only licence does not permit imports. Ask about GDP inspections, and about GMP where the partner manufactures or repackages, and ask to see the history of findings and corrective actions, not only the certificate.

The second blind spot is the portfolio. A partner that already carries a competing product in your ATC class will not prioritise yours, whatever it promises. The third is language coverage: a partner with no presence of its own in the Romandie and Ticino leaves roughly a quarter of the market uncovered.

• Betriebsbewilligung covering the activities you need: import, wholesale, batch release
• Fachtechnisch verantwortliche Person named, with a real workload and a deputy
• GDP inspection history and, where manufacture or repackaging occurs, GMP status with findings
• Portfolio screened for competing products in your ATC class, generics included
• Its own presence and field force in German-speaking Switzerland, the Romandie and Ticino
• Hospital tender capability: references with purchasing groups and cantonal hospitals
• Track record on pricing dossiers with the Federal Office of Public Health (FOPH) and the Spezialitätenliste
• Pharmacovigilance system with a contact person in Switzerland and documented reporting deadlines
• A contracted transfer of the authorisation back to you on termination, with a deadline and costs

Which contract terms actually decide the deal?

Five points decide it: who holds the authorisation, who owns the dossier and the trademark, whether the deal runs on transfer price or commission, who bears the Swissmedic fees, and what happens to the authorisation and the stock on termination. Everything else is detail.

On a transfer price you sell to the partner, it carries the inventory risk and earns the difference; your margin is fixed and the end price is out of your hands. On commission the product stays yours, the partner takes a percentage of sales, and you carry stock and receivables. The commission model requires a marketing-authorisation holder of your own but leaves you in charge of price.

Settle the fees explicitly: the application, every variation, the annual fee per authorisation and the cost of translations into three languages. Record that the dossier and the trademark belong to you and that the partner holds only a licence to use them. Minimum commitments should be tied to market data rather than wishful numbers, and the notice period should cover a realistic window for transferring the authorisation back, as a rule six to twelve months.

• Name who holds the authorisation and the Betriebsbewilligung
• Transfer price or commission, with the price basis and the adjustment mechanism defined
• Who bears the cost of the application, of variations and of the annual fee
• Ownership of dossier, trademark and pack design, with a mere licence to use for the partner
• Minimum purchases or minimum sales, tied to verifiable market data
• Term and notice period, aligned with how long a transfer back really takes
• Treatment of stock, recalls and open pharmacovigilance duties on termination

What do foreign teams underestimate about Switzerland?

Four things: absolute size, trilingualism, price regulation and parallel imports. Around nine million inhabitants means high prices per pack but small unit numbers. A product that delivers volume in Germany delivers margin in Switzerland, on a fraction of the quantity.

Trilingualism is not a marketing question but a regulatory one: Fachinformation, Patienteninformation and packaging texts must exist in German, French and Italian and be carried through three times with every change. Then comes the price mechanism: the Publikumspreis is built from the Fabrikabgabepreis plus the Vertriebsanteil plus VAT, and the Vertriebsanteil is regulated, not freely negotiable.

For reimbursed products the Federal Office of Public Health (FOPH) reviews Spezialitätenliste prices periodically against a foreign price comparison and a therapeutic cross-comparison. Price cuts are the normal case, not the exception. The Abgabekategorie also decides channel and advertising rights: prescription-only products may not be advertised to the public. And because Swiss prices sit above the European level, parallel imports are a permanent factor in your calculation.

• Around nine million inhabitants: high prices per pack, small absolute volumes
• Three language regions: triple product information and triple packaging texts
• Price build-up of Fabrikabgabepreis, regulated Vertriebsanteil and Publikumspreis
• Periodic FOPH review of the Spezialitätenliste with a foreign price comparison
• The Abgabekategorie determines the channel and whether public advertising is allowed
• Parallel imports compress margins in segments with a wide price gap to abroad

How does the search actually run?

Budget four to nine months from long list to signature. The effort is not in finding candidates but in checking them: licences, portfolio, language coverage and references take time, and negotiating who holds the authorisation is the longest item.

Start with a long list from the public Swissmedic lists of marketing-authorisation holders and establishment licences, extended by the partners already carrying products in your indication. Cut to five to eight candidates, assess them in a structured way and insist in every case on a written market entry plan with sales assumptions, a price assumption and a timeline.

1. Build a long list from the Swissmedic lists of authorisation holders and establishment licences, 2 to 4 weeks
2. Decide the model: own authorisation, service provider, partner holding the authorisation, or logistics mandate, 2 weeks
3. Form a shortlist of five to eight candidates and put confidentiality agreements in place, 3 to 4 weeks
4. Check licences, inspection history, portfolio and language coverage on documents, 4 to 6 weeks
5. Request and compare written market entry plans with sales, price and timing assumptions, 4 weeks
6. Visit two finalists on site, including the warehouse, the quality system and a meeting with the fachtechnisch verantwortliche Person, 2 to 3 weeks
7. Negotiate commercial terms and who holds the authorisation, 6 to 12 weeks
8. Sign, trigger the transfer or grant of the authorisation at Swissmedic and plan the SL submission to the FOPH, 4 to 8 weeks

Which red flags should you raise?

Red flags are rarely bad faith, mostly overreach: a partner promises coverage, channels and speed that its licences and its team cannot carry. In every case ask for the document rather than the assurance.

The most effective question is always the one that asks for evidence: the licence as a copy, the inspection report with its date, the reference with a name and a phone number, the FOPH price decision with its file reference. A partner who cannot supply three such items within two weeks will not supply them after signature either.